Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bendazac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.70 |
| ▸ | CNR1 | P21554 | 4/20 | 0.70 |
| ▸ | ACHE | P22303 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendazac SCHEMBL30299455 | 1.00 | CNR2 (0.70) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| Bendazac SCHEMBL11689792 | 0.99 | CNR2 (0.68) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL8415791 | 0.91 | CNR1 (0.59) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL9186085 | 0.91 | CNR1 (0.58) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL11691268 | 0.90 | CNR2 (0.68) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL6966754 | 0.89 | CNR2 (0.67) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL12608904 | 0.89 | CNR2 (0.67) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| Bendazac SCHEMBL1649722 | 0.88 | CNR2 (0.65) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL28910049 | 0.87 | CNR1 (0.64) | CNR2CNR1ACHEKDM4ECYP1A2 | |
| SCHEMBL8673918 | 0.86 | CNR2 (0.58) | CNR2CNR1ACHEKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9396 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116850183-B | Methods and pharmaceutical compositions for treating myopia | GRAND PHARMA (CHINA) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119317433-A | Methods for treating cushing's syndrome and liver disease and reducing hepatotoxicity of other drugs taken by patients | 科赛普特治疗学股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| EP-4470565-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-12-04 | — | — | EP | claimed |
| CN-118975562-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118742325-A | Methods for preventing or treating diseases or conditions associated with antineoplastic agents | 上海岸阔医药科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| EP-4429635-A1 | SELF-EMULSIFYING OIL-IN-WATER MICROEMULSION OR NANOEMULSION, AND EMULSIFYING COMPOSITION | URSAPHARM Arzneimittel GmbH (DE) | 2024-09-18 | — | — | EP | claimed |
| US-4748174-A | NONSTEROIDAL ANTIINFLAMMATORY AND ANALGESIC DRUGS | THERAPICON S.R.L. (IT) | 1988-05-31 | — | — | US | claimed |
| EP-0255967-A1 | Method of treating contact lenses | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1988-02-17 | — | — | EP | claimed |
| EP-0245126-A2 | Percutaneous absorption preparation and process for preparing same | Ogiso, Taro (JP) | 1987-11-11 | — | — | EP | claimed |
| US-4554288-A | ORAL OR TOPICAL ADMINISTRATION | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1985-11-19 | — | — | US | claimed |
| EP-0131317-A2 | Use of Benzadac and of its salts for the manufacture of a medicament for the treatment of retinitis pigmentosa | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1985-01-16 | — | — | EP | claimed |
| US-4455146-A | THERMOPLASTIC ELASTOMERS, OILS OR FATTY ACID, TACKFIER, AND A MEDICINE | HISAMITSU PHARMACEUTICAL CO., LTD. (JP) | 1984-06-19 | — | — | US | claimed |
| US-4451477-A | Bendazac treatment of cataract | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1984-05-29 | — | — | US | claimed |
| EP-0072462-A2 | Pharmaceutical preparations | Toko Yakuhin Industry Co., Ltd. (JP) | 1983-02-23 | — | — | EP | claimed |
| US-4352813-A | ANTILIPEMIC AGENTS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1982-10-05 | — | — | US | claimed |
| US-4001219-A | STEROIDAL DERIVATIVES OF BENDAZOLIC ACID AND PROCESS FOR THE PREPARATION OF THE SAME | BAIOCCHI LEANDRO | 1977-01-04 | — | — | US | claimed |